DHCR7 sirna

DHCR7 siRNA (Human)

Cat. Num. AAA8230056

• Gene Names: DHCR7; SLOS
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: DHCR7; DHCR7 siRNA (Human); D7SR; 7-dehydrocholesterol reductase; 7-DHC reductase; Putative sterol reductase SR-2; Sterol Delta(7)-reductase; DHCR7 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: DHCR7 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 475

• Applicable Applications for DHCR7 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DHCR7 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for DHCR7 sirna

siRNA to inhibit DHCR7 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 255308875
• NCBI GeneID: 1717
• NCBI Accession #: NP_001157289.1
• NCBI GenBank Nucleotide #: NM_001163817.1
• UniProt Accession #: Q9UBM7; O60492; O60717; B2R6Z2
• Molecular Weight: 54,489 Da
• NCBI Official Full Name: 7-dehydrocholesterol reductase
• NCBI Official Synonym Full Names: 7-dehydrocholesterol reductase
• NCBI Official Symbol: DHCR7
• NCBI Official Synonym Symbols: SLOS
• NCBI Protein Information: 7-dehydrocholesterol reductase
• UniProt Protein Name: 7-dehydrocholesterol reductase
• Protein Family: Probable 7-dehydrocholesterol reductase
• UniProt Gene Name: DHCR7
• UniProt Synonym Gene Names: D7SR; 7-DHC reductase
• UniProt Entry Name: DHCR7_HUMAN

NCBI Description

This gene encodes an enzyme that removes the C(7-8) double bond in the B ring of sterols and catalyzes the conversion of 7-dehydrocholesterol to cholesterol. This gene is ubiquitously expressed and its transmembrane protein localizes to the endoplasmic reticulum membrane and nuclear outer membrane. Mutations in this gene cause Smith-Lemli-Opitz syndrome (SLOS); a syndrome that is metabolically characterized by reduced serum cholesterol levels and elevated serum 7-dehydrocholesterol levels and phenotypically characterized by mental retardation, facial dysmorphism, syndactyly of second and third toes, and holoprosencephaly in severe cases to minimal physical abnormalities and near-normal intelligence in mild cases. Alternative splicing results in multiple transcript variants that encode the same protein.[provided by RefSeq, Aug 2009]

Uniprot Description

DHCR7: Production of cholesterol by reduction of C7-C8 double bond of 7-dehydrocholesterol (7-DHC). Defects in DHCR7 are the cause of Smith-Lemli-Opitz syndrome (SLOS); also known as SLO syndrome or RSH syndrome. SLOS is an autosomal recessive frequent inborn disorder of sterol metabolism with characteristic congenital malformations and dysmorphias. All patients suffer from mental retardation. Children with SLOS have elevated serum 7-dehydrocholesterol (7- DHC) levels and low serum cholesterol levels. SLOS occurs in relatively high frequency: approximately 1 in 20,000 to 30,000 births in populations of northern and central European background. Historically, a clinical distinction often was made between classic ('type I') SLOS and the more severely affected ('type II') patients. There is, in reality, a clinical and biochemical continuum from mild to severe SLOS. Belongs to the ERG4/ERG24 family.

Protein type: EC 1.3.1.21; Oxidoreductase; Lipid Metabolism - steroid biosynthesis; Membrane protein, multi-pass; Membrane protein, integral

Chromosomal Location of Human Ortholog: 11q13.4

Cellular Component: nuclear outer membrane; endoplasmic reticulum membrane; membrane; endoplasmic reticulum; integral to membrane

Molecular Function: 7-dehydrocholesterol reductase activity

Biological Process: blood vessel development; regulation of cholesterol biosynthetic process; multicellular organism growth; cell differentiation; cholesterol biosynthetic process; lung development; regulation of cell proliferation; post-embryonic development

Disease: Smith-lemli-opitz Syndrome